Research map: Evaluating the Prognostic Impact of IDH Mutations in Intrahepatic Cholangiocarcinoma

Back to the article

Papers in this map

  1. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 · John G. Doench · 2016 · 5174 citations · Cited by this paper
  2. Prediction of Anthracycline Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early-Stage Breast Cancer by the MammaPrint 70-Gene Signature for Patients Enrolled in the FLEX Study · 2026 · Related
  3. Cholangiocarcinoma 2020: the next horizon in mechanisms and management · Jesús M. Bañales · 2020 · 2542 citations · Cited by this paper
  4. Integrated Radioproteomic Modeling for Early Recurrence Prediction and Metabolic Characterization in Hepatocellular Carcinoma · 2026 · Related
  5. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) · Donavan T. Cheng · 2015 · 2209 citations · Cited by this paper
  6. Hypoalbuminemia as a Predictive Biomarker of Dyspnea Response to Dexamethasone and Placebo in Patients With Cancer: Secondary Analysis of the ABCD Randomized Clinical Trial · 2026 · Related
  7. Genomic spectra of biliary tract cancer · Hiromi K. Nakamura · 2015 · 1323 citations · Cited by this paper
  8. Development and Validation of a Computational Histology Artificial Intelligence–Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials · 2026 · Related
  9. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer · Do‐Youn Oh · 2022 · 1210 citations · Cited by this paper
  10. Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study · 2026 · Related
  11. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial · Robin Kate Kelley · 2023 · 1156 citations · Cited by this paper
  12. Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I · 2026 · Related
  13. Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise · Supriya Kumar Saha · 2016 · 818 citations · Cited by this paper
  14. DNA Damage Response Alterations and Immune Checkpoint Blockade Outcomes Across Multiple Cancers · 2026 · Related
  15. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate · Lenny Dang · 2010 · 617 citations · Cited by this paper
  16. Genomic Landscape of GNAQ and GNA11 Mutations in Metastatic Solid Tumors: A Real-World Data Analysis · 2026 · Related
  17. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation · Andrew Xiuxuan Zhu · 2021 · 513 citations · Cited by this paper
  18. Personalized Molecular Monitoring of a Cryptic DIAPH1::PDGFRB Fusion in Chronic Eosinophilic Leukemia Using Droplet Digital Polymerase Chain Reaction · 2026 · Related
  19. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas · Pu Wang · 2012 · 399 citations · Cited by this paper
  20. Real-World Genomic Characteristics and Prognostic Association in Advanced Papillary Thyroid Carcinoma · 2026 · Related
  21. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review · Audra N. Boscoe · 2019 · 212 citations · Cited by this paper
  22. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma · Thomas Boerner · 2021 · 171 citations · Cited by this paper
  23. Epidemiology of cholangiocarcinoma · Maria Qurashi · 2023 · 165 citations · Cited by this paper
  24. Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets · Andrew Xiuxuan Zhu · 2014 · 149 citations · Cited by this paper
  25. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma · Lipika Goyal · 2015 · 135 citations · Cited by this paper
  26. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma · Bingqi Ma · 2020 · 96 citations · Cited by this paper
  27. Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma · Shao‐Lai Zhou · 2021 · 70 citations · Cited by this paper
  28. Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies · Samantha Brown · 2021 · 53 citations · Cited by this paper
  29. Surgical Treatment of Intrahepatic Cholangiocarcinoma: Current and Emerging Principles · Eliza Wright Beal · 2020 · 51 citations · Cited by this paper
  30. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing · Juan Putra · 2015 · 47 citations · Cited by this paper
  31. Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma · Margherita Rimini · 2022 · 21 citations · Cited by this paper
  32. Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue · Giovanni Brandi · 2023 · 13 citations · Cited by this paper
  33. Impact of IDH1 mutation on clinical course of patients with intrahepatic cholangiocarcinoma: a retrospective analysis from a German tertiary center · Maximilian N. Kinzler · 2023 · 9 citations · Cited by this paper
  34. IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future Therapies · Alexander Bray · 2025 · 8 citations · Cited by this paper
  35. Untitled · Cited by this paper

Source: OpenAlex (CC0)